Compare · ELVN vs NVO
ELVN vs NVO
Side-by-side comparison of Enliven Therapeutics Inc. (ELVN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELVN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 60.3x ELVN ($2.88B).
- ELVN has been more active in the news (11 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 13 for ELVN).
- Company
- Enliven Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $2.88B
- $173.66B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 11
- 4
- Recent ratings
- 13
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ELVN
- SEC Form 4 filed by Enliven Therapeutics Inc.
- SEC Form 3 filed by Enliven Therapeutics Inc.
- SEC Form 8-K filed by Enliven Therapeutics Inc.
- Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
- Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
- SEC Form 4 filed by Enliven Therapeutics Inc.
- Morgan Stanley initiated coverage on Enliven Therapeutics with a new price target
- SEC Form 144 filed by Enliven Therapeutics Inc.
- Analyst initiated coverage on Enliven Therapeutics with a new price target
- CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 3,982 shares at a strike of $14.85 and sold $303,003 worth of shares (6,018 units at $50.35) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 38,000 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank